Physician profile
Patrick B Reeves
NPI 1003253410
$6,055.93
in general payments reported to CMS, 2019-2025
33 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $522 · 2021: $793 · 2022: $948 · 2023: $945 · 2024: $1,156 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,139 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,138.84 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $845.38 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Astrazeneca Pharmaceuticals Lp | $679.58 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $532.45 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Novartis Pharmaceuticals Corporation | $504.32 | 2023-2025 | |
| Vifor Pharma, INC. | $478.83 | 2019-2024 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $291.44 | 2019-2024 | Rayaldee |
| Daiichi Sankyo INC. | $257.18 | 2019-2022 | |
| Glaxosmithkline, LLC. | $248.65 | 2021-2025 | Benlysta, Arexvy |
| Novo Nordisk INC | $238.09 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Alexion Pharmaceuticals, INC. | $230.57 | 2019-2025 | Ultomiris |
| Travere Therapeutics, INC. | $193.90 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $193.07 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $178.08 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $173.90 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $145.23 | 2021-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $139.88 | 2019-2025 | Voyxact, Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.00 | 2023-2025 | Jardiance |
| Pharmacosmos Therapeutics INC. | $83.62 | 2024-2025 | Monoferric |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $80.68 | 2021-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $64.99 | 2020-2024 | Terlivaz |
| Mallinckrodt Enterprises LLC | $59.98 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.48 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $48.03 | 2023 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $44.68 | 2019-2022 | |
| Shield Therapeutics INC | $36.08 | 2025 | |
| Lilly USA, LLC | $22.19 | 2023 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $18.27 | 2022 | |
| Genentech USA, INC. | $15.42 | 2019 | |
| Chiesi USA, INC. | $15.27 | 2022 | |
| Scpharmaceuticals INC. | $14.34 | 2025 | |
| Ardelyx, INC. | $13.97 | 2024 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $12.79 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Reeves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.